Oncomatrix Signs an Agreement With the University of Stuttgart to Develop New Drugs for Treating Tumor Metastases
12/11/2012 10:47:50 AM
DERIO, Spain--(BUSINESS WIRE)--Oncomatrix, a biopharmaceutical company from the Basque country, Spain, develops personalized treatments for invasive tumors. Oncomatrix has signed an agreement with the University of Stuttgart to develop new drugs with tumor targeted activity. This partnership will allow the development of immunoconjugates able to attack the cells involved in metastasis in invasive breast and pancreas cancers.
comments powered by